US NIH allocates additional funding to develop pyrimidinedione product as an anti-HIV drug

The US based ImQuest Pharmaceuticals Inc., a strategic partner of Samjin Pharmaceutical Co., has rectntly received an additional funding of $2.3 million from the National Institute of Allergy and Infectious Disease (NIAID/NIH) to support the development of pyrimidinedione inhibitors as topical microbicides to prevent the sexual transmission of HIV.

The NIH grant provides funding for the cont...